Various immune-mediated cellular pathways such as that of TNF-α, IL-23, and IL-17 are involved in the pathophysiology of psoriasis and psoriatic arthritis, and their understanding has led to remarkably better control of it.4,7 Nowadays, there are various treatment options that are already approved by the regulatory bodies and rely on blocking those cytokines with good to excellent results so far. The gene discussed is IL17A; the disease is psoriasis.